EMA
approval
· 2026-08-19
EMA Authorised: Kaftrio (ivacaftor;tezacaftor;elexacaftor) — Vertex Pharmaceuticals (Ireland) Limited
Summary
The EMA authorises Kaftrio (ivacaftor; tezacaftor; elexacaftor) for cystic fibrosis, with Vertex Pharmaceuticals (Ireland) Limited as the marketing authorizatio…
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Status: Authorised. Therapeutic area: Cystic Fibrosis. MAH: Vertex Pharmaceuticals (Ireland) Limited. Decision date: 23/07/2026. Orphan medicine